Skip to main content
Erschienen in: Pathology & Oncology Research 1/2019

28.10.2017 | Original Article

MicroRNA Expression in Laser Micro-dissected Breast Cancer Tissue Samples – a Pilot Study

verfasst von: Edward Seclaman, Diana Narita, Andrei Anghel, Natalia Cireap, Razvan Ilina, Ioan Ovidiu Sirbu, Catalin Marian

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer continues to represent a significant public health burden despite outstanding research advances regarding the molecular mechanisms of cancer biology, biomarkers for diagnostics and prognostic and therapeutic management of this disease. The studies of micro RNAs in breast cancer have underlined their potential as biomarkers and therapeutic targets; however most of these studies are still done on largely heterogeneous whole breast tissue samples. In this pilot study we have investigated the expression of four micro RNAs (miR-21, 145, 155, 92) known to be involved in breast cancer, in homogenous cell populations collected by laser capture microdissection from breast tissue section slides. Micro RNA expression was assessed by real time PCR, and associations with clinical and pathological characteristics were also explored. Our results have confirmed previous associations of miR-21 expression with poor prognosis characteristics of breast cancers such as high stage, large and highly proliferative tumors. No statistically significant associations were found with the other micro RNAs investigated, possibly due to the small sample size of our study. Our results also suggest that miR-484 could be a suitable endogenous control for data normalization in breast tissues, these results needing further confirmation by future studies. In summary, our pilot study showed the feasibility of detecting micro RNAs expression in homogenous laser captured microdissected invasive breast cancer samples, and confirmed some of the previously reported associations with poor prognostic characteristics of breast tumors.
Literatur
1.
Zurück zum Zitat Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, Satheesha S et al (2010) Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res 70:4778–4784CrossRefPubMedPubMedCentral Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, Satheesha S et al (2010) Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res 70:4778–4784CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245–5250CrossRefPubMed Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245–5250CrossRefPubMed
3.
Zurück zum Zitat Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ et al (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Bio 8:R214CrossRef Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ et al (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Bio 8:R214CrossRef
4.
5.
Zurück zum Zitat Chen J, Wang X (2014) MicroRNA-21 in breast cancer: diagnostic and prognostic potential. Clin Transl Oncol 16:225–233CrossRefPubMed Chen J, Wang X (2014) MicroRNA-21 in breast cancer: diagnostic and prognostic potential. Clin Transl Oncol 16:225–233CrossRefPubMed
6.
Zurück zum Zitat Chen L, Li Y, Fu Y, Peng J, Mo MH, Stamatakos M et al (2013) Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One 8:e54213CrossRefPubMedPubMedCentral Chen L, Li Y, Fu Y, Peng J, Mo MH, Stamatakos M et al (2013) Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One 8:e54213CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N (2008) Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 9:76CrossRefPubMedPubMedCentral Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N (2008) Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 9:76CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403CrossRef Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403CrossRef
9.
Zurück zum Zitat Fetica B, Balacescu O, Balacescu L, Rus M, Berindan-Neagoe I (2014) An alternative and sensitive method based on LCM and Q-PCR for HER2 testing in breast cancer. Cancer Biomark 14:129–135CrossRefPubMed Fetica B, Balacescu O, Balacescu L, Rus M, Berindan-Neagoe I (2014) An alternative and sensitive method based on LCM and Q-PCR for HER2 testing in breast cancer. Cancer Biomark 14:129–135CrossRefPubMed
10.
Zurück zum Zitat Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, et al (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 105:13021–13026 Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, et al (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 105:13021–13026
11.
Zurück zum Zitat Hagrass HA, Sharaf S, Pasha HF, Tantawy EA, Mohamed RH, Kassem R (2015) Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer. Genes Cancer 6:281–287PubMedPubMedCentral Hagrass HA, Sharaf S, Pasha HF, Tantawy EA, Mohamed RH, Kassem R (2015) Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer. Genes Cancer 6:281–287PubMedPubMedCentral
12.
Zurück zum Zitat Hannafon BN, Sebastiani P, De Las Morenas A, Lu J, Rosenberg CL (2011) Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res 13:R24CrossRefPubMedPubMedCentral Hannafon BN, Sebastiani P, De Las Morenas A, Lu J, Rosenberg CL (2011) Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res 13:R24CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Hasemeier B, Christgen M, Kreipe H, Lehmann U (2008) Reliable microRNA profiling in routinely processed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology. BMC Biotechnol 8:90CrossRefPubMedPubMedCentral Hasemeier B, Christgen M, Kreipe H, Lehmann U (2008) Reliable microRNA profiling in routinely processed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology. BMC Biotechnol 8:90CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y et al (2012) Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 33:828–834CrossRefPubMed Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y et al (2012) Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 33:828–834CrossRefPubMed
15.
Zurück zum Zitat Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. (2008) The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10:202–210 Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. (2008) The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10:202–210
16.
Zurück zum Zitat Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T et al (2009) Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Investig 89:597–606CrossRefPubMed Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T et al (2009) Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Investig 89:597–606CrossRefPubMed
17.
Zurück zum Zitat Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065–7070CrossRefPubMed Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065–7070CrossRefPubMed
18.
Zurück zum Zitat Iorio MV, Casalini P, Tagliabue E, Menard S, Croce CM (2008) MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer 44:2753–2759CrossRefPubMed Iorio MV, Casalini P, Tagliabue E, Menard S, Croce CM (2008) MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer 44:2753–2759CrossRefPubMed
19.
Zurück zum Zitat Khoshnaw SM, Powe DG, Ellis IO, Green AR (2011) Detection and quantification of microRNAs in laser-microdissected formalin-fixed paraffin-embedded breast cancer tissues. Methods Mol Biol 755:119–142CrossRefPubMed Khoshnaw SM, Powe DG, Ellis IO, Green AR (2011) Detection and quantification of microRNAs in laser-microdissected formalin-fixed paraffin-embedded breast cancer tissues. Methods Mol Biol 755:119–142CrossRefPubMed
20.
Zurück zum Zitat Klopfleisch R, Weiss AT, Gruber AD (2011) Excavation of a buried treasure DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. Histol Histopathol 26:797–810PubMed Klopfleisch R, Weiss AT, Gruber AD (2011) Excavation of a buried treasure DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. Histol Histopathol 26:797–810PubMed
21.
Zurück zum Zitat Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS et al (2014) Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol 8:874–883CrossRefPubMedPubMedCentral Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS et al (2014) Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol 8:874–883CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Kong W, Zhao JJ, He L, Cheng JQ (2009) Strategies for profiling microRNA expression. J Cell Physiol 218:22–25CrossRefPubMed Kong W, Zhao JJ, He L, Cheng JQ (2009) Strategies for profiling microRNA expression. J Cell Physiol 218:22–25CrossRefPubMed
23.
Zurück zum Zitat Liu H, McDowell TL, Hanson NE, Tang X, Fujimoto J, Rodriguez-Canales J (2014) Laser capture microdissection for the investigative pathologist. Vet Pathol 51:257–269CrossRefPubMed Liu H, McDowell TL, Hanson NE, Tang X, Fujimoto J, Rodriguez-Canales J (2014) Laser capture microdissection for the investigative pathologist. Vet Pathol 51:257–269CrossRefPubMed
24.
Zurück zum Zitat Lou G, Ma N, Xu Y, Jiang L, Yang J, Wang C et al (2015) Differential distribution of U6 (RNU6-1) expression in human carcinoma tissues demonstrates the requirement for caution in the internal control gene selection for microRNA quantification. Int J Mol Med 36(5):1400–1408CrossRefPubMed Lou G, Ma N, Xu Y, Jiang L, Yang J, Wang C et al (2015) Differential distribution of U6 (RNU6-1) expression in human carcinoma tissues demonstrates the requirement for caution in the internal control gene selection for microRNA quantification. Int J Mol Med 36(5):1400–1408CrossRefPubMed
25.
Zurück zum Zitat Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838CrossRefPubMed Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838CrossRefPubMed
26.
Zurück zum Zitat Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682–688CrossRefPubMed Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682–688CrossRefPubMed
27.
Zurück zum Zitat Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P et al (2013) Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 34:163–169CrossRefPubMedPubMedCentral Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P et al (2013) Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 34:163–169CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Mattiske S, Suetani RJ, Neilsen PM, Callen DF (2012) The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomark Prev 21:1236–1243CrossRef Mattiske S, Suetani RJ, Neilsen PM, Callen DF (2012) The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomark Prev 21:1236–1243CrossRef
29.
Zurück zum Zitat Min W, Wang B, Li J, Han J, Zhao Y, Su W et al (2014) The expression and significance of five types of miRNAs in breast cancer. Med Sci Monit Basic Res 20:97–104PubMedPubMedCentral Min W, Wang B, Li J, Han J, Zhao Y, Su W et al (2014) The expression and significance of five types of miRNAs in breast cancer. Med Sci Monit Basic Res 20:97–104PubMedPubMedCentral
30.
Zurück zum Zitat Murray GI (2011) Laser Capture Microdissection: Methods and Protocols. Methods in molecular biology. Springer Murray GI (2011) Laser Capture Microdissection: Methods and Protocols. Methods in molecular biology. Springer
31.
Zurück zum Zitat Narita D, Anghel A, Seclaman E, Ilina R, Cireap N, Ursoniu S (2010) Molecular profiling of ADAM12 gene in breast cancers. Romanian J Morphol Embryol 51:669–676 Narita D, Anghel A, Seclaman E, Ilina R, Cireap N, Ursoniu S (2010) Molecular profiling of ADAM12 gene in breast cancers. Romanian J Morphol Embryol 51:669–676
32.
Zurück zum Zitat Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES et al (2013) Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 8:e53141CrossRefPubMedPubMedCentral Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES et al (2013) Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 8:e53141CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Nilsson S, Moller C, Jirstrom K, Lee A, Busch S, Lamb R et al (2012) Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. PLoS One 7:e36051CrossRefPubMedPubMedCentral Nilsson S, Moller C, Jirstrom K, Lee A, Busch S, Lamb R et al (2012) Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. PLoS One 7:e36051CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Pan F, Mao H, Deng L, Li G, Geng P (2014) Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. Int J Clin Exp Pathol 7:5622–5633PubMedPubMedCentral Pan F, Mao H, Deng L, Li G, Geng P (2014) Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. Int J Clin Exp Pathol 7:5622–5633PubMedPubMedCentral
35.
Zurück zum Zitat Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP (2004) Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett 26:509–515CrossRefPubMed Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP (2004) Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett 26:509–515CrossRefPubMed
36.
Zurück zum Zitat Rice J, Roberts H, Rai SN, Galandiuk S (2015) Housekeeping genes for studies of plasma microRNA: A need for more precise standardization. Surgery 158(5):1345–1351CrossRefPubMed Rice J, Roberts H, Rai SN, Galandiuk S (2015) Housekeeping genes for studies of plasma microRNA: A need for more precise standardization. Surgery 158(5):1345–1351CrossRefPubMed
37.
Zurück zum Zitat Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, Elton TS et al (2008) Real-time PCR quantification of precursor and mature microRNA. Methods 44:31–38CrossRefPubMedPubMedCentral Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, Elton TS et al (2008) Real-time PCR quantification of precursor and mature microRNA. Methods 44:31–38CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY (2007) miR-21-mediated tumor growth. Oncogene 26:2799–2803CrossRefPubMed Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY (2007) miR-21-mediated tumor growth. Oncogene 26:2799–2803CrossRefPubMed
39.
Zurück zum Zitat Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H et al (2013) Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 139:223–229CrossRefPubMed Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H et al (2013) Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 139:223–229CrossRefPubMed
40.
Zurück zum Zitat Siebolts U, Varnholt H, Drebber U, Dienes HP, Wickenhauser C, Odenthal M (2009) Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J Clin Pathol 62:84–88CrossRefPubMed Siebolts U, Varnholt H, Drebber U, Dienes HP, Wickenhauser C, Odenthal M (2009) Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J Clin Pathol 62:84–88CrossRefPubMed
41.
Zurück zum Zitat Silver N, Best S, Jiang J, Thein SL (2006) Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC Mol Biol 7:33CrossRefPubMedPubMedCentral Silver N, Best S, Jiang J, Thein SL (2006) Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC Mol Biol 7:33CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Society AC. Cancer Facts & Figures 2015 (2015) Atlanta: American Cancer Society Society AC. Cancer Facts & Figures 2015 (2015) Atlanta: American Cancer Society
43.
Zurück zum Zitat Stahel R, Bogaerts J, Ciardiello F, de Ruysscher D, Dubsky P, Ducreux M, et al (2015) Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. Cancer Treat Rev 41:129–135 Stahel R, Bogaerts J, Ciardiello F, de Ruysscher D, Dubsky P, Ducreux M, et al (2015) Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. Cancer Treat Rev 41:129–135
44.
Zurück zum Zitat Stefani G, Slack FJ (2008) Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 9:219–230CrossRefPubMed Stefani G, Slack FJ (2008) Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 9:219–230CrossRefPubMed
45.
Zurück zum Zitat Sun EH, Zhou Q, Liu KS, Wei W, Wang CM, Liu XF et al (2014) Screening miRNAs related to different subtypes of breast cancer with miRNAs microarray. Eur Rev Med Pharmacol Sci 18:2783–2788PubMed Sun EH, Zhou Q, Liu KS, Wei W, Wang CM, Liu XF et al (2014) Screening miRNAs related to different subtypes of breast cancer with miRNAs microarray. Eur Rev Med Pharmacol Sci 18:2783–2788PubMed
46.
Zurück zum Zitat Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034 Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034
47.
Zurück zum Zitat Wang J, Wu J (2012) Role of miR-155 in breast cancer. Front Biosci (Landmark Ed) 17:2350–2355CrossRef Wang J, Wu J (2012) Role of miR-155 in breast cancer. Front Biosci (Landmark Ed) 17:2350–2355CrossRef
48.
Zurück zum Zitat Wang F, Hou J, Jin W, Li J, Yue Y, Jin H et al (2014) Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis. Molecules 19:6282–6293CrossRefPubMedPubMedCentral Wang F, Hou J, Jin W, Li J, Yue Y, Jin H et al (2014) Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis. Molecules 19:6282–6293CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K et al (2007) Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13:1668–1674CrossRefPubMedPubMedCentral Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K et al (2007) Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13:1668–1674CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S et al (2014) miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer 13:220CrossRefPubMedPubMedCentral Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S et al (2014) miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer 13:220CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A et al (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 103:9136–9141CrossRefPubMedPubMedCentral Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A et al (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 103:9136–9141CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ et al (2012) MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle 11:2137–2145CrossRefPubMedPubMedCentral Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ et al (2012) MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle 11:2137–2145CrossRefPubMedPubMedCentral
Metadaten
Titel
MicroRNA Expression in Laser Micro-dissected Breast Cancer Tissue Samples – a Pilot Study
verfasst von
Edward Seclaman
Diana Narita
Andrei Anghel
Natalia Cireap
Razvan Ilina
Ioan Ovidiu Sirbu
Catalin Marian
Publikationsdatum
28.10.2017
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0343-y

Weitere Artikel der Ausgabe 1/2019

Pathology & Oncology Research 1/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.